Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

isdin s.a. - ciclopirox - barniz de uÑas medicamentoso - 80 mg/g - ciclopirox 80 mg - ciclopirox

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios reig jofre, s.a. - ciclopirox olamina - champÚ - 15 mg/g - ciclopirox olamina 15 mg - ciclopirox

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

isdin s.a. - ciclopirox olamina - champÚ - 15 mg/g - ciclopirox olamina 15 mg - ciclopirox

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios serra pamies s.a. - ciclopirox olamina - champÚ - 15 mg/g - ciclopirox olamina 15 mg - ciclopirox

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios serra pamies s.a. - ciclopirox - barniz de uÑas medicamentoso - 80 mg/g - ciclopirox 80 mg - ciclopirox

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

qualix pharma s.l - ciclopirox olamina - champÚ - 15 mg/g - ciclopirox olamina 15 mg - ciclopirox

USA - engelsk - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - ciclopirox olamine (unii: 50md4sb4ap) (ciclopirox - unii:19w019zdrj) - ciclopirox 7.7 mg in 1 ml - ciclopirox topical suspension usp, 0.77% (lotion) is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to trichophyton   rubrum , trichophyton   mentagrophytes , epidermophyton   floccosum , and microsporum   canis ; cutaneous candidiasis (moniliasis) due to candida albicans ; and tinea (pityriasis) versicolor due to malassezia furfur . ciclopirox topical suspension usp, 0.77% (lotion) is contraindicated in individuals who have shown hypersensitivity to any of its components.

USA - engelsk - NLM (National Library of Medicine)

fougera pharmaceuticals inc. - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - ciclopirox 10 mg in 0.96 ml - ciclopirox shampoo 1% is indicated for the topical treatment of seborrheic dermatitis of the scalp in adults. none. teratogenic effects: pregnancy category b there are no adequate or well-controlled studies in pregnant women. therefore, ciclopirox shampoo 1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. oral embryofetal developmental studies were conducted in mice, rats, rabbits and monkeys. ciclopirox or ciclopirox olamine was orally administered during the period of organogenesis. no maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 77, 125, 80 and 38.5 mg/kg/day ciclopirox in mice, rats, rabbits and monkeys, respectively (approximately 13, 42, 54 and 26 times the maximum recommended human dose based on body surface area comparisons, respectively). dermal embryofetal developmental studies were conducted in rats and rabbits with ciclopirox olamine dissolved in peg 400. ciclopirox olamine was topically administered

USA - engelsk - NLM (National Library of Medicine)

actavis pharma, inc. - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - ciclopirox 10 mg in .96 ml - ciclopirox shampoo 1% is indicated for the topical treatment of seborrheic dermatitis of the scalp in adults. none. teratogenic effects: pregnancy category b there are no adequate or well-controlled studies in pregnant women. therefore, ciclopirox shampoo 1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. oral embryofetal developmental studies were conducted in mice, rats, rabbits and monkeys. ciclopirox or ciclopirox olamine was orally administered during the period of organogenesis. no maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 77, 125, 80 and 38.5 mg/kg/day ciclopirox in mice, rats, rabbits and monkeys, respectively (approximately 13, 42, 54 and 26 times the maximum recommended human dose based on body surface area comparisons, respectively). dermal embryofetal developmental studies were conducted in rats and rabbits with ciclopirox olamine dissolved in peg 400. ciclopirox olamine was topically administere

USA - engelsk - NLM (National Library of Medicine)

padagis israel pharmaceuticals ltd - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - ciclopirox 1 g in 100 ml - ciclopirox shampoo, 1% is indicated for the topical treatment of seborrheic dermatitis of the scalp in adults. none. teratogenic effects: pregnancy category b there are no adequate or well-controlled studies in pregnant women. therefore, ciclopirox shampoo, 1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. oral embryofetal developmental studies were conducted in mice, rats, rabbits and monkeys. ciclopirox or ciclopirox olamine was orally administered during the period of organogenesis. no maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 77, 125, 80 and 38.5 mg/kg/day ciclopirox in mice, rats, rabbits and monkeys, respectively (approximately 13, 42, 54 and 26 times the maximum recommended human dose based on body surface area comparisons, respectively). dermal embryofetal developmental studies were conducted in rats and rabbits with ciclopirox olamine dissolved in peg 400. ciclopirox olamine was topically administered during the period of organogenesis. no maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 92 mg/kg/day and 77 mg/kg/day ciclopirox in rats and rabbits, respectively (approximately 31 and 54 times the maximum recommended human dose based on body surface area comparisons, respectively). it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when ciclopirox shampoo, 1% is administered to a nursing woman. no clinical trials have been conducted in subjects younger than 16 years. in clinical trials, the safety and tolerability of ciclopirox shampoo, 1% in the population 65 years and older was comparable to that of younger subjects. results of the efficacy analysis in those subjects 65 years and older showed effectiveness in 25 of 85 (29%) subjects treated with ciclopirox shampoo, 1%, and in 15 of 61 (25%) subjects treated with the vehicle; due to the small sample size, a statistically significant difference was not demonstrated. other reported clinical experience has not identified differences in responses between the elderly and younger subjects, but greater sensitivity to adverse effects in some older individuals cannot be ruled out.